69,756 Shares in Dianthus Therapeutics, Inc. $DNTH Acquired by Deutsche Bank AG

Deutsche Bank AG acquired a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 69,756 shares of the company’s stock, valued at approximately $6,800,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in shares of Dianthus Therapeutics in the 2nd quarter worth $27,000. First Horizon Corp acquired a new position in Dianthus Therapeutics during the first quarter worth $32,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Dianthus Therapeutics in the fourth quarter valued at $40,000. Russell Investments Group Ltd. bought a new position in shares of Dianthus Therapeutics in the third quarter valued at $64,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after buying an additional 3,317 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on DNTH shares. Wedbush boosted their target price on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. HC Wainwright raised their price target on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Truist Financial boosted their price objective on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $124.27.

Dianthus Therapeutics Stock Performance

Shares of DNTH stock opened at $110.07 on Tuesday. The company has a market capitalization of $6.02 billion, a price-to-earnings ratio of -26.52 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 52-week low of $22.81 and a 52-week high of $117.88. The company has a 50-day simple moving average of $101.30 and a two-hundred day simple moving average of $85.62.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The firm had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. On average, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, SVP Adam M. Veness sold 16,167 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $110.38, for a total value of $1,784,513.46. Following the transaction, the senior vice president owned 3,833 shares of the company’s stock, valued at approximately $423,086.54. The trade was a 80.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Simon Read sold 2,778 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $117.55, for a total value of $326,553.90. Following the completion of the transaction, the director owned 2,778 shares of the company’s stock, valued at $326,553.90. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 287,084 shares of company stock valued at $29,615,923 in the last ninety days. 3.02% of the stock is owned by corporate insiders.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.